Advertisement

Topics

USPTO invalidates J&J’s patent on prostate cancer drug Zytiga

08:27 EST 18 Jan 2018 | Pharmaceutical Business Review

The US Patent & Trademark Office (USPTO) has invalidated a Johnson & Johnson (J&J) patent on prostate cancer drug Zytiga (abiraterone acetate).

Original Article: USPTO invalidates J&J’s patent on prostate cancer drug Zytiga

NEXT ARTICLE

More From BioPortfolio on "USPTO invalidates J&J’s patent on prostate cancer drug Zytiga"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...